Related Experiment Videos
Formulating paclitaxel in nanoparticles alters its disposition
Teng Kuang Yeh1, Ze Lu, M Guillaume Wientjes
1College of Pharmacy, The Ohio State University, Columbus, OH, USA.
Pharmaceutical Research
|June 11, 2005
Summary
Paclitaxel nanoparticle formulations show altered tissue distribution compared to the standard Cremophor/ethanol formulation. Nanoparticles lead to faster clearance and preferential accumulation in organs like the liver and kidneys.
Area of Science:
- Pharmacology
- Nanotechnology
- Oncology
Background:
- Paclitaxel is a key chemotherapy drug for solid tumors.
- The standard formulation uses Cremophor/ethanol (C/E) as solubilizers.
- Novel formulations, including nanoparticles, are being developed.
Purpose of the Study:
- To evaluate the impact of paclitaxel-loaded gelatin nanoparticles on tissue distribution.
- To compare nanoparticle formulation with the conventional C/E formulation.
Main Methods:
- Mice received intravenous injections of paclitaxel-loaded gelatin nanoparticles or the C/E formulation.
- Plasma and tissue pharmacokinetics were analyzed.
- Drug concentrations were measured in various organs.
Main Results:
- Nanoparticle formulation resulted in a 40% smaller area under the blood concentration-time curve and faster blood clearance.
- Significant differences in tissue distribution were observed between formulations.
- Nanoparticles showed higher and sustained accumulation in the liver, small intestine, and kidneys (8-fold increase in kidneys).
Conclusions:
- Paclitaxel formulation significantly influences its pharmacokinetic profile and tissue distribution.
- Gelatin nanoparticles alter paclitaxel disposition, leading to preferential organ accumulation.
- This suggests formulation-dependent therapeutic and toxicity profiles.